Retatrutide is a once-weekly weight loss injection that combines the actions of three key metabolic hormones: GLP-1 (helps you feel full and keeps blood sugar in balance) GIP (supports insulin release and helps your body process food for energy) Glucagon (tells your body to burn fat for energy) This triple G mechanism sets it apart from Wegovy, which targets one hormone, and Mounjaro, which targets two
Caleb Alexander, a professor of epidemiology and medicine at the Johns Hopkins Bloomberg School of Public Health
Market Segment Insights The market displays a notable distribution among its segment types, notably 'Short-acting', 'Long-acting', and 'Dual-action'
Your cousins friend who sells it from a cooler
However, the American Medical Association, the Endocrine Society, and the Obesity Medicine Association all recommend considering pharmacotherapy for patients with my BMI and comorbidity profile
The progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) tells a clear story about where obesity treatment is heading